Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Evelo Biosciences Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Evelo Biosciences Inc market cap is $939,600.00.
What is the 52-week high for Evelo Biosciences Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Evelo Biosciences Inc 52 week high is $13.93 as of September 16, 2025.
What is the 52-week low for Evelo Biosciences Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Evelo Biosciences Inc 52 week low is $0.028 as of September 16, 2025.
What is Evelo Biosciences Inc stock price today?
Evelo Biosciences Inc stock price today is $0.0419.
What was Evelo Biosciences Inc stock price yesterday?
Evelo Biosciences Inc stock price yesterday was $0.0495.
What is the PE ratio of Evelo Biosciences Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Evelo Biosciences Inc’s P/E ratio is 0.00.
What is the Price-to-Book ratio of Evelo Biosciences Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Evelo Biosciences Inc P/B ratio is -0.0349.
What is Evelo Biosciences Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Evelo Biosciences Inc's EBITDA is -1.21.
What is the 50-day moving average of Evelo Biosciences Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Evelo Biosciences Inc 50-day moving average is $0.051.
